Pyxis Oncology, Inc.
No enriched coverage for $PYXS in the last 7 days.
GordonMD Global Investments, a 10% owner of Pyxis Oncology (NASDAQ:PYXS), acquired 5.5 million shares and 7.5 million warrants on October 1, 2026, at $0 per share. The stock trades at $2.19, down 23% in a week but up 48% over six months. Analysts raised price targets to $8-$19, citing positive clinical trial data for its cancer treatment.
GordonMD Global Investments LP purchased 5,517,000 indirectly-held shares of Pyxis Oncology, Inc. (PYXS) on 2026-10-01. Filed jointly with GordonMD Long Biased Master Fund LP (10% owner), GordonMD Long Biased GP LLC (10% owner) and Gordon Craig D (10% owner).
Pyxis Oncology (PYXS) closed a public offering, raising $110M upfront. The deal includes milestone-linked warrants that could add $172.6M if exercised, totaling $282.6M. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering involved new and existing institutional investors.
Recent PYXS coverage spans corporate actions, earnings and financial news.
In the last 30 days, PYXS insiders filed 1 SEC Form 4 transaction — 1 purchase and no sales. The most active reporter was GordonMD Global Investments LP with 1 filing.
The stake increase signals confidence and may support the stock price.
Insider purchase suggests confidence, likely supporting short-term price upside.
The capital raise provides significant funding for clinical development, likely supporting near-term share price stability or modest upside.
The sizable capital infusion supports the MICVO Phase 3 trial and working capital, reducing financing risk but adding dilution.
The offering provides significant cash but dilutes existing shareholders; market reaction may be mixed.
AlphAI scores every news story that mentions PYXS with an AI model for sentiment and relevance, and aggregates insider trades from Pyxis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GordonMD Global Investments, a 10% owner of Pyxis Oncology (NASDAQ:PYXS), acquired 5.5 million shares and 7.5 million warrants on October 1, 2026, at $0 per share. The stock trades at $2.19, down 23% in a week but up 48% over six months. Analysts raised price targets to $8-$19, citing positive clinical trial data for its cancer treatment.
2 min readGordonMD Global Investments LP purchased 5,517,000 indirectly-held shares of Pyxis Oncology, Inc. (PYXS) on 2026-10-01. Filed jointly with GordonMD Long Biased Master Fund LP (10% owner), GordonMD Long Biased GP LLC (10% owner) and Gordon Craig D (10% owner).
1 min readPyxis Oncology (PYXS) closed a public offering, raising $110M upfront. The deal includes milestone-linked warrants that could add $172.6M if exercised, totaling $282.6M. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering involved new and existing institutional investors.
1 min readPyxis Oncology (PYXS) raised $102.8M in a public offering of common stock and warrants, priced at $2.90 per share. The offering was led by Leerink, Guggenheim, and Wells Fargo. Proceeds will support clinical development and corporate needs, including the Phase 3 Headliner trial.
1 min readPyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 29, 2026, Pyxis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as repre
2 min readPyxis Oncology (PYXS) plans a public offering of common stock, pre-funded warrants, and common warrants. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering is subject to market conditions and stockholder approval. Leerink, Guggenheim, and Wells Fargo are joint bookrunners.
2 min readPyxis Oncology (PYXS) reported positive Phase 1 data for MICVO in 2L+ head and neck cancer, showing 36% cORR and 94% DCR. Median PFS was 6.2 months, with 79% 12-month survival. No new safety signals were observed. Pyxis plans a Phase 3 trial in mid-2027, pending FDA alignment. PYXS stock is down 16.95% in pre-market trading.
2 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min readPyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clin
2 min readPro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
2 min read
